GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (NAS:FATE) » Definitions » E10

FATE (Fate Therapeutics) E10 : $-1.91 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fate Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Fate Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.400. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.91 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-14), Fate Therapeutics's current stock price is $1.83. Fate Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-1.91. Fate Therapeutics's Shiller PE Ratio of today is .


Fate Therapeutics E10 Historical Data

The historical data trend for Fate Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics E10 Chart

Fate Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -6.52 -1.81 -1.86

Fate Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.86 -1.86 -1.90 -1.90 -1.91

Competitive Comparison of Fate Therapeutics's E10

For the Biotechnology subindustry, Fate Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fate Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Shiller PE Ratio falls into.



Fate Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fate Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.4/133.0289*133.0289
=-0.400

Current CPI (Sep. 2024) = 133.0289.

Fate Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -0.300 99.070 -0.403
201503 -0.380 99.621 -0.507
201506 -0.330 100.684 -0.436
201509 -0.240 100.392 -0.318
201512 -0.260 99.792 -0.347
201603 -0.290 100.470 -0.384
201606 -0.290 101.688 -0.379
201609 -0.270 101.861 -0.353
201612 -0.210 101.863 -0.274
201703 -0.240 102.862 -0.310
201706 -0.230 103.349 -0.296
201709 -0.260 104.136 -0.332
201712 -0.290 104.011 -0.371
201803 -0.270 105.290 -0.341
201806 -0.370 106.317 -0.463
201809 -0.310 106.507 -0.387
201812 -0.250 105.998 -0.314
201903 -0.300 107.251 -0.372
201906 -0.360 108.070 -0.443
201909 -0.400 108.329 -0.491
201912 -0.370 108.420 -0.454
202003 -0.440 108.902 -0.537
202006 -0.350 108.767 -0.428
202009 -0.680 109.815 -0.824
202012 -0.610 109.897 -0.738
202103 -0.480 111.754 -0.571
202106 -0.580 114.631 -0.673
202109 -0.450 115.734 -0.517
202112 -0.720 117.630 -0.814
202203 -0.680 121.301 -0.746
202206 -0.790 125.017 -0.841
202209 -0.860 125.227 -0.914
202212 -0.580 125.222 -0.616
202303 -0.190 127.348 -0.198
202306 -0.540 128.729 -0.558
202309 -0.460 129.860 -0.471
202312 -0.450 129.419 -0.463
202403 -0.470 131.776 -0.474
202406 -0.330 132.554 -0.331
202409 -0.400 133.029 -0.400

Add all the adjusted EPS together and divide 10 will get our e10.


Fate Therapeutics  (NAS:FATE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Fate Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Fate Therapeutics Business Description

Traded in Other Exchanges
Address
12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
Yuan Xu director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Dulac Edward J Iii officer: Chief Financial Officer FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
J Scott Wolchko director, officer: President and CEO C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Bahram Valamehr officer: Chief Development Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Cindy Tahl officer: See Remarks C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Yu-waye Chu officer: See Remarks FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
John Mendlein director
Mark Plavsic officer: Chief Technical Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karin Jooss director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Robert S Epstein director